1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Verrucous Carcinoma Global Clinical Trials Review, H1, 2015

Verrucous Carcinoma Global Clinical Trials Review, H1, 2015

Summary

GlobalData's clinical trial report, “Verrucous Carcinoma Global Clinical Trials Review, H1, 2015" provides data on the Verrucous Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Verrucous Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Verrucous Carcinoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Verrucous Carcinoma Global Clinical Trials Review, H1, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Verrucous Carcinoma 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in North America 10
Top Countries Contributing to Clinical Trials in Middle East and Africa 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Verrucous Carcinoma to Oncology Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Verrucous Carcinoma to Oncology Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Verrucous Carcinoma 21
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Prominent Drugs 26
Clinical Trial Profiles 27
Clinical Trial Overview of Top Companies 27
MatrixPharm 27
Clinical Trial Overview of MatrixPharm 27
Clinical Trial Overview of Top Institutes / Government 28
National Cancer Institute 28
Clinical Trial Overview of National Cancer Institute 28
Roswell Park Cancer Institute 31
Clinical Trial Overview of Roswell Park Cancer Institute 31
Fox Chase Cancer Center 32
Clinical Trial Overview of Fox Chase Cancer Center 32
Ohio State University Comprehensive Cancer Center 33
Clinical Trial Overview of Ohio State University Comprehensive Cancer Center 33
Radiation Therapy Oncology Group 34
Clinical Trial Overview of Radiation Therapy Oncology Group 34
University of Chicago 35
Clinical Trial Overview of University of Chicago 35
Wake Forest University 36
Clinical Trial Overview of Wake Forest University 36
Abramson Cancer Center 37
Clinical Trial Overview of Abramson Cancer Center 37
AIDS Malignancy Clinical Trials Consortium 38
Clinical Trial Overview of AIDS Malignancy Clinical Trials Consortium 38
Case Comprehensive Cancer Center 39
Clinical Trial Overview of Case Comprehensive Cancer Center 39
Five Key Clinical Profiles 40
Appendix 69
Abbreviations 69
Definitions 69
Research Methodology 70
Secondary Research 70
About GlobalData 71
Contact Us 71
Disclaimer 71
Source 71

List of Tables
Verrucous Carcinoma Therapeutics, Global, Clinical Trials by Region, 2015* 6
Verrucous Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Verrucous Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Verrucous Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 9
Verrucous Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2015* 10
Verrucous Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 11
Verrucous Carcinoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 12
Proportion of Verrucous Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2015* 13
Verrucous Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 14
Verrucous Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 15
Proportion of Verrucous Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2015* 16
Verrucous Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2015* 17
Verrucous Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 18
Verrucous Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 19
Verrucous Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 20
Verrucous Carcinoma Therapeutics, Global, Suspended Clinical Trials, 2015* 21
Verrucous Carcinoma Therapeutics, Global, Withdrawn Clinical Trials, 2015* 21
Verrucous Carcinoma Therapeutics, Global, Terminated Clinical Trials, 2015* 22
Verrucous Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 23
Verrucous Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 24
Verrucous Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 25
Verrucous Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 26
Verrucous Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by MatrixPharm, 2015* 27
Verrucous Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015* 28
Verrucous Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2015* 31
Verrucous Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fox Chase Cancer Center, 2015* 32
Verrucous Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Ohio State University Comprehensive Cancer Center, 2015* 33
Verrucous Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Radiation Therapy Oncology Group, 2015* 34
Verrucous Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Chicago, 2015* 35
Verrucous Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Wake Forest University, 2015* 36
Verrucous Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Abramson Cancer Center, 2015* 37
Verrucous Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by AIDS Malignancy Clinical Trials Consortium, 2015* 38
Verrucous Carcinoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2015* 39

List of Figures
Verrucous Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Verrucous Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Verrucous Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Verrucous Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 9
Verrucous Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 10
Verrucous Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 11
Proportion of Verrucous Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2015* 13
Verrucous Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 14
Verrucous Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 15
Proportion of Verrucous Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2015* 16
Verrucous Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2015* 17
Verrucous Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 18
Verrucous Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 19
Verrucous Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 20
Verrucous Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 23
Verrucous Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 24
Verrucous Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 26
GlobalData Methodology 70

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.